MiNK Therapeutics Presents agenT-797 Phase II Data
Analysis based on 7 articles · First reported Apr 03, 2026 · Last updated Apr 03, 2026
The announcement of clinical trial data for agenT-797 by MiNK Therapeutics is expected to positively impact the biotechnology and pharmaceutical markets, particularly in the oncology sector. Positive results could lead to increased investment in MiNK Therapeutics and similar cell therapy companies, signaling advancements in cancer treatment.
MiNK Therapeutics announced that data from an investigator-initiated Phase II trial of its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The trial, conducted at Memorial Sloan Kettering Cancer Center, evaluates agenT-797 in combination with botensilimab and balstilimab for patients with PD-1 refractory gastroesophageal cancer. This study aims to address the significant unmet need in patients resistant to checkpoint inhibition by re-engaging the immune system. Jennifer Buell, President and CEO of MiNK Therapeutics, emphasized the importance of these data in understanding immune reprogramming and treatment sequencing for durable outcomes in refractory cancers. Samuel L. Cytryn will present the findings on April 20, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard